Skip to main content

Table 1 Patient demographics

From: Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients

Characteristic

All patients (N = 145)a

Oropharyngeal (n = 76)a

Non-oropharyngeal (n = 69)a

p value*

Age, median years (range)

63 (28–86)

59.5 (32–83)

67 (28–86)

<0.01

Sex, n (%)

   

0.5

 Male

115 (79)

62 (82)

53 (77)

 

 Female

30 (21)

14 (18)

16 (23)

 

ECOG PS, n (%)

   

<0.001

 0

102 (70)

64 (84)

38 (55)

 

 1

32 (22)

10 (13)

22 (32)

 

 2

10 (7)

2 (3)

8 (12)

 

 Missing

1 (1)

-

1 (1)

 

Smoking status, n (%)

   

0.2

 Non-smoker

44 (30)

24 (32)

20 (29)

 

 Ex-smoker

61 (42)

36 (47)

25 (36)

 

 Current smoker

37 (26)

15 (20)

22 (32)

 

 Missing

3 (2)

1 (1)

2 (3)

 

Tumour site, n (%)

   

<0.001

 Lip and oral cavity

25 (17)

0 (0)

25 (36)

 

 Nasopharynx

8 (6)

0 (0)

8 (12)

 

 Oropharynx

76 (52)

76 (100)

0 (0)

 

 Hypopharynx

12 (8)

0 (0)

12 (17)

 

 Larynx

24 (17)

0 (0)

24 (35)

 

Tumour stage, n (%)

   

0.05

 T1

35 (24)

24 (32)

11 (16)

 

 T2

52 (36)

29 (38)

23 (33)

 

 T3

36 (25)

15 (19)

21 (30)

 

 T4

22 (15)

8 (11)

14 (20)

 

Nodal stage, n (%)

   

<0.001

 N0

44 (30)

11 (14)

33 (48)

 

 N1

36 (25)

22 (29)

14 (20)

 

 N2

60 (41)

41 (54)

19 (28)

 

 N3

5 (3)

2 (3)

3 (4)

 

AJCC stage, n (%)

   

0.2

 I

9 (6)

4 (5)

5 (7)

 

 II

35 (24)

18 (24)

17 (25)

 

 III

74 (51)

44 (58)

30 (43)

 

 IV

27 (19)

10 (13)

17 (27)

 

p16 tumour status, n (%)

   

<0.001

 Negative

48 (51)

7 (16)

41 (80)

 

 Positive

47 (49)

37 (84)

10 (20)

 

 Missing

50

32

19

 

Treatment, n (%)

   

<0.001

 Radiotherapy

17 (12)

10 (13)

7 (10)

 

 Postoperative radiotherapy

29 (20)

3 (4)

26 (38)

 

 Chemoradiotherapy

88 (61)

61 (80)

27 (39)

 

 Postoperative chemoradiotherapy

11 (8)

2 (3)

9 (13)

 

 Neutrophils, median counts (range) x 109 cells/L

5.10 (1.10 - 11.90)

4.60 (1.10 - 11.90)

5.30 (2.10 - 11.80)

0.2

 Lymphocytes, median counts (range) x 109 cells/L

1.60 (0.20 - 10.70)

1.60 (0.40 - 3.40)

1.70 (0.20 - 10.70)

0.1

 NLR, median counts (range) x 109 cells/L

3.11 (0.41 - 29.75)

3.11 (1.30 - 29.75)

3.11 (0.41 - 16.00)

0.9

NLR, n (%)

   

0.7

 Low (≤5)

116 (80)

60 (79)

56 (81)

 

 High (>5)

29 (20)

16 (21)

13 (19)

 
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer and NLR neutrophil-to-lymphocyte ratio
  2. *, appropriate statistical test (Students t-test, Mann Whitney-U, χ2 test or Fishers exact test) conducted between oropharyngeal and non-oropharyngeal cancer patient excluding missing values and a, missing values indicated in table
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us